HF 2022: HELIOS-A: Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis | Dr Garcia-Pavia

Подробнее о видео

Watch on Radcliffe Cardiology:

In this short interview, Dr Pablo Garcia-Pavia (Hospital Universitario Puerta de Hierro Majadahonda, ES) shares the findings from the phase 3 study, HELIOS-A (). The study, presented at Heart Failure 2022, investigated the efficacy and safety of vutrisiran (ALN-TTRSC02) in patients with hereditary transthyretin amyloidosis (hATTR amyloidosis).

Discussion Points
1. Study Background
2. Vutrisiran
3. Study Design, Eligibility Criteria & Outcome Measures
4. Key Findings
5. Take-Home Messages
6. Next Steps

Recorded at Heart Failure 2022, Madrid.

Videographers: Oliver Miles, Tom Green and Mike Knight
Interviewer: Mirjam Boros

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.